MEDICINOVA, INC. Other Comprehensive Income (Loss), Net of Tax
MEDICINOVA, INC. (MNOV) reported Other Comprehensive Income (Loss), Net of Tax of -$11.11 thousand for the 12-month period ending 2012-12-31, per its 10-K filed 2013-03-28.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2013-03-28
- MEDICINOVA, INC. other comprehensive income (loss), net of tax for fiscal 2012 was -$11.11K.
- MEDICINOVA, INC. other comprehensive income (loss), net of tax for fiscal 2011 was -$1.14K, a 112.41% decline from fiscal 2010.
- MEDICINOVA, INC. other comprehensive income (loss), net of tax for fiscal 2010 was $9.21K.
- MEDICINOVA, INC. other comprehensive income (loss), net of tax for fiscal 2009 was -$35.17K, a 134.57% decline from fiscal 2008.
| Period end | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|
| 2012-12-31 | -$11.11K 10-K · filed 2013-03-28 |
| 2011-12-31 | -$1.14K 10-K · filed 2013-03-28 |
| 2010-12-31 | $9.21K 10-K · filed 2013-03-28 |
| 2009-12-31 | -$35.17K 10-K · filed 2013-03-28 |
| 2008-12-31 | $101.72K 10-K · filed 2013-03-28 |
| 2007-12-31 | -$82.26K 10-K · filed 2013-03-28 |
| 2006-12-31 | -$34.02K 10-K · filed 2013-03-28 |
| 2005-12-31 | -$15.19K 10-K · filed 2013-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |